A doctor uses hyaluronic acid fillers on his aging patient's hands. His patient suffers complications and sues for medical malpractice, alleging that the doctor used the product for a non-FDA approved purpose.
David J. Goldberg, M.D. J.D.Dr. Hands, a prominent dermatologist, has recently been using hyaluronic acid fillers to treat aging hands. He knows that calcium hydroxyapatite filers are FDA approved for the hands; hyaluronic acid fillers, although FDA approved for several facial indications, are not cleared by the FDA for use on the hands.
Recently, Dr. Hands injected a woman’s hands with hyaluronic acid and she unfortunately suffered a complications from the treatment. She has sued him for medical malpractice and alleges that he used the product for a non-FDA approved purpose. Should Dr. Hands be concerned about this particular allegation?
The Food and Drug Administration (FDA) is the federal agency that is responsible for regulating the safety, efficacy, marketing and distribution of medical drugs and devices (including hyaluronic acid fillers). Although the FDA imposes very rigorous standards for the approval (more appropriately termed “clearance”) of medical drugs and devices, it does permit physicians to exercise their authority in determining the most proper form of treatment for their patients. Such treatments often involve the use of drugs or devices for uses other than those for which they have been approved by the FDA.
Use of drugs in this manner (“off-label”) does not require additional approval by the FDA. Off-label use is not only recognized by, but, as has been suggested by some, is often encouraged by the FDA. The use of drugs and devices for conditions that are not otherwise indicated is widespread among physicians and is generally not considered experimental or investigational.
Off-label use of drugs is even a necessity in some medical specialties, especially in the areas of pediatrics and terminal illnesses. Off-label use is particularly necessary in these areas because the majority of medications that undergo review and approval by the FDA are tested on adults only, and because terminally ill patients have often exhausted the repertoire of available treatments.
NEXT: Courts and FDA face numerous challenges
Courts and the FDA face numerous challenges in balancing the interest in regulating the distribution and marketing of drugs and devices, with the interest in allowing physicians to determine the best course of treatment for their patients. The FDA is actually prohibited from interfering with physician authority concerning off-label use of drugs or devices, as enumerated in § 214 of the Food and Drug Administration Modernization Act of 1997 (“FDAMA”).
A common misconception is that off-label use of drugs or devices is somehow experimental or investigative. It is important to note that the focus of medical therapy, or the practice of medicine, is the well-being of the patient, whereas the focus of investigative research is to test a particular hypothesis. The use of drugs, or devices, for indications not specifically approved by the FDA does not generally constitute investigative research. Because the FDA expects that physicians will exercise discretion in their prescribing patterns, the FDA states very specifically that doctors are expected to use their “best knowledge and judgment” when practicing their specialties.
Patients, through off-label physician use, are given access to a great number of drugs and devices that they would not otherwise have access to if the FDA was to expand on its current regulatory authority. Some studies estimate that anywhere from 25% to 60% of prescribed drugs are for off-label uses.
It should also be noted that, despite the common view among many physicians, doctors do not have an obligation to disclose the FDA regulatory status for a drug or device to their patients. Physicians, courts have noted, are in the best position to determine treatments for their patients. They are involved in the practice of medicine on a daily basis and have person-to-person contact with the recipients of medications and devices that are being administered for off-label uses. Physicians, it is argued, regularly consult colleagues, attend continuing education courses, and research scholarly journals. They are, therefore, best able to determine the safety and effectiveness of off-label drug and device use. The FDA itself is clearly incapable of reviewing proposals for every potential use of a drug or device.
ALSO READ: I operated on the wrong ear
Dr. Hands may or may not lose the medical malpractice brought against him. However, he is not likely to lose the case because he used hyaluronic acid fillers for an off-label purpose.